Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Current Assets (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Current Assets for 13 consecutive years, with $63.2 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 29.68% to $63.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $63.2 million through Dec 2025, down 29.68% year-over-year, with the annual reading at $82.1 million for FY2025, 31.98% down from the prior year.
  • Current Assets hit $63.2 million in Q4 2025 for Vistagen Therapeutics, down from $78.9 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $128.1 million in Q4 2023 to a low of $11.6 million in Q2 2023.
  • Historically, Current Assets has averaged $74.2 million across 5 years, with a median of $80.5 million in 2025.
  • Biggest five-year swings in Current Assets: surged 6488.88% in 2021 and later crashed 78.95% in 2023.
  • Year by year, Current Assets stood at $86.8 million in 2021, then crashed by 69.97% to $26.1 million in 2022, then soared by 391.66% to $128.1 million in 2023, then decreased by 29.8% to $89.9 million in 2024, then dropped by 29.68% to $63.2 million in 2025.
  • Business Quant data shows Current Assets for VTGN at $63.2 million in Q4 2025, $78.9 million in Q3 2025, and $66.7 million in Q2 2025.